Therapeutic strategies for Alzheimer’s disease (AD) often involve inhibiting acetylcholinesterase (AChE), underscoring the need for novel inhibitors with high selectivity and minimal side effects. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.